Rubella-Brown et al.
It is confirmed that little reliance can be placed on statements concerning a past history of rubella. In this series about one-third of all firm statements were proved to be wrong on subsequent laboratory investigation. The histories, mostly obtained from parents, were most accurate for the 1-5 years age group. Similar findings have been reported by other workers (Vesikari et al., 1968) . This lack of correlation between statements concerning a past history of rubella and serological studies may be ascribed to the difficulty in diagnosis of rubella which is often simulated clinically by other infections (Krugman, 1965) . Ignorance of infection may also be due partly to the occurrence of subclinical attacks, and, to a certain extent, failure to remember the occurrence of clinical infection many years in the past.
The results of this and previous serological studies of children seem to raise a number of important problems concerning vaccination against rubella. Several vaccines have been developed and the results of preliminary clinical trials published (Proceedings of the 23rd Symposium on Microbiological Standardization, Rubella Vaccines, 1969) . Before these vaccines become freely available the age at which they are to be administered must be decided. As yet, insufficient data have been published concerning the possible transmission of vaccine strains of rubella virus across the placenta and the teratogenic effects of these strains on the fetus. Consequently, the vaccination of adult women will involve the prevention of pregnancy immediately before and after administration of the vaccine. If children are to be vaccinated, it must be taken into consideration that the majority are already naturally immune by the age of 10-15 years, and mass vaccination at this stage may be regarded as impracticable or uneconomical. The selection of children on the basis of past histories cannot be relied on, and the alternative screening of all children to detect immune status prior to vaccination would be very laborious. The vaccination of infants below the age of 5 years may be more logical, as this age group has the lowest level of natural immunity. In this case, however, vaccine-induced immunity may not be sufficient to afford protection into adulthood, and it may be necessary to revaccinate in later years. Summary: Seventy-nine patients with chronic bronchitis were randomly allotted to four treatment regimens-placebo throughout the winter months for five years; tetracycline for the first two winters and placebo for the next three; placebo for the first two winters and tetracycline for the next three; and tetracycline for five winters. In addition all groups received a five-day course of tetracycline for any acute exacerbation. There was a significant reduction in the number of exacerbations among the more susceptible patients-that is, those who suffered more than one exacerbation each winter. Though the average decline in F.E.V.1 over the five-year period was less in the treated groups this was not statistically significant. There was no significant difference between the groups in respect of lung volumes, diffusing capacity, and blood gases.
Introduction
Optimal antibiotic regimens for chronic recurrent mucopurulent bronchitis are difficult to assess, being complicated by the plethora of antibiotics available. It is still uncertain whether patients on chemoprophylaxis during the winter months fare better than those receiving prompt treatment of acute exacerbations. Further, can the lung function of these patients be preserved better by chemoprophylaxis ?
The (1965) -that is, M=mucoid, Tr.=trace of pus, + =25% of pus in specimen, + + -50% pus in specimen, + ++ =75% of pus in specimen. Each winter, and immediately preceding the start of treatment, patients submitted two consecutive early morning sputum specimens. Films were examined for pus cells and eosinophils. The specimens were subjected to a pancreatic digest method and inoculated on blood agar. Sensitivity tests to the standard antibiotics were carried out. Specimens sent by post at the start of exacerbations were treated similarly, and at the end of each winter period two early morning sputum specimens were examined as before.
Patients were seen at 28-day intervals, the following data being recorded: any exacerbation of bronchitis associated with purutent sputum, the number of days off work, the use of BRITSH MEDICAL JOURNAL emergency treatment, any other chemotherapy, and any drug intolerance. In addition, the patient brought a 24-hour sputum specimen collected during the preceding day and the volume and appearance were recorded. Patients were provided with diary sheets to record daily any change in chest symptoms and the colour of the early morning sputum. Current weekly consumption of cigarettes was recorded. The patient was asked about any lapse in treatment and the number of tablets remaining were counted to see if there had been any serious omission in therapy. Urine tests for the presence of tetracycline were arranged on two random occasions each winter.
At the end of each winter the following additional information was noted: the grade of dyspnoea, any change of occupation, and the patient's assessment of his chest disability compared with the previous winter. The last was graded as worse (-1) , no change (0), slightly improved (+ 1), and much improved (+ 2) , and the sum of these five assessments by each patient was recorded as the " patient score." The total number of days lost from work because of exacerbations of bronchitis was noted for every patient each winter, and in addition our medical social worker obtained an independent assessment from the Ministry of Pensions and National Insurance of the loss of working-time due to bronchitis.
Pulmonary Function
Tests were carried out on patients in the autumn before the trial started and in the spring following the completion of the fifth winter of treatment. The studies were done on an outpatient basis and patients were not tested during an exacerbation of bronchitis. Vital capacity (V.C.) and the forced expiratory one-second volume (F.E.V.,) were Those results which are expressed as a percentage of the predicted normal values have been derived from the formulae of Needham et al. (1954) corrected to body temperature, pressure, and saturation (B.T.P.S.). These normal values were chosen because they were obtained from subjects in an adjacent geographical area in the North-East of Scotland. The F.E.V.1 was predicted from the formula for the maximum breathing capacity (M.B.C.) divided by a factor of 35 and the total lung capacity (T.L.C.) from the addition of the predicted values for V.C. and R.V.
Plan of Treatment
The aim was a double-blind study comparing tetracycline 500 mg. b.d. with a placebo administered from October to April for five winters. In addition, an anti-influenza vaccine was given in October 1964 and again in October 1966. Patients were instructed that when they developed an exacerbation with increasing purulence of the sputum they should post a specimen of sputum direct to the laboratory and start emergency tetracycline 500 mg. b.d. for five days in addition to existing treatment.
The tetracycline and placebo tablets were packed in bottles containing sufficient to last 30 days. These bottles were labelled 1 to 10, with a random allocation of tetracycline to five and a random allocation of patients to numbers 1-10. The first allocation covered the first two winters. A fresh batch was issued at the start of the third winter with a reallocation of tetracycline/placebo to numbers 1-10. The effect was to produce four treatment groups-namely, group "P." who received a placebo throughout, group " T." who received tetracycline throughout, group " T.P." who received tetracycline for two winters and then placebo for three, and group " P.T." who received placebo for two winters and then tetracycline for three. The change in medication at the start of the third winter was unknown to the patients and medical staff.
Results
Of the 120 patients accepted for the trial 41 were excluded-9 because of incorrect preliminary assessment, 7 died, 1 left Dundee, and 24 were defaulters.
Age.-The average age and range for the four groups were: group P. 53 (40-59), group T.P. 51 (38-60), group P.T. 53 (38-60), and group T. 51 (47-58) years.
Type of Work.-The type of work and exposure to dust and fumes showed a slight preponderance of heavy work with dust and fumes in groups T. and T.P., but the differences were not significant.
The smoking history and change in smoking habit during the five-year period are shown in Table I . 
Analysis of Number of Exacerbations
The relation of exacerbations to treatment is shown in Table IV . There is a progressive improvement in the average with increasing duration of treatment, but again the differences are not significant. The number of emergency treatments differed only slightly from the number of exacerbations, and the averages were: P. 5-3, T.P. 33, P.T. 2-8, and T. 22.
The days lost from work owing to exacerbations of bronchitis during the winter months of the trial were recorded first according to the patient's statement, and then compared with the National Health Insurance records. The average number of days lost from work owing to exacerbations of bronchitis were: None of these comparisons showed a significant advantage for the groups receiving chemoprophylaxis. If, however, we ignore the previous groupings and analyse the number of exacerbations related to treatment or placebo both during the first two and the latter three years of the trial there is a significant advantage (P<0 025) on both occasions. The results are shown in Table V . The effect of chemoprophylaxis was most evident on those prone to many exacerbations. Thus all 10 patients who had more than one exacerbation per year on placebo were better when receiving regular tetracycline. These differences were tested further by examining groups T.P. and P.T.-that is, those receiving both placebo and treatment-so that each patient was his own control. The average number of exacerbations was calculated for each patient for the placebo and treatment periods and the differences were compared. The results are shown in Table VI . If treatment had been without Streptococcus pneumoniae and Haemophilus influenzae were isolated at some time in 72 of the 79 patients (absent in one in group P., three in group T.P., and three in group T.). Coagulase-positive staphylococci resistant to tetracycline appeared in the sputum of four patients in group P., eight in group T.P., eight in group P.T., and four in group T.-that is, a total of 24 patients. In five of the eight in group T.P. but in none of the other groups, these organisms were present in pretreatment cultures. Among these 24 patients these staphylococci may have contributed to clinical relapses in five, but the evidence was doubtful. Thus, coagulase-positive staphylococci occurred no more frequently in those receiving regular winter chemoprophylaxis.-Tetracycline-resistant pneurnococci appeared in only three patients (one in group T.P., one in group P.T., and one in group T.). Proteus was isolated 114 times in 24 patients. In one patient in group P. this organism was present initially and throughout the trial and was the only pathogen in eight exacerbations.
Drug Acceptance
Though the number of tablets remaining was checked in front of each patient at every visit, this was not regarded as a completely reliable estimate of drug acceptance. We encouraged patients to report any side-effects or difficulties with their medication. A total of 700 urine specimens from 79 patients were sent to the research laboratories of Pfizer Limited and examined for tetracycline by a bioassay method: 575 (82%) were positive. Further analysis showed that only seven patients were not taking their drugs regularly. 
Sputum Studies
Over the five-year period there was a reduction of sputum volume in all groups (P. -8-7 ml., T.P. -4 0 ml., P.T. -14 1 ml., and T. -17 7 ml.). The sputum appearance during the six winter months of the five winters was examined in 73 patients. We have recorded as purulent only specimens containing 25% or more of pus. There was a trend of clearing sputum with increasing duration of treatment, but the differences were not statistically significant: Paco2 . .
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In the other measurements the changes in mean value did not appear to favour the treated groups more than the placebo group and there was no statistical difference in results. The percentage fall in T.L.C. and the rise in RV./T.L.C. was due to greater reduction in V.C. than in R.V. The deterioration in DLCo/V.A. and Sao2 is in the expected direction, but it is difficult to explain the fall in mean Paco, in all groups. There was no obvious systematic bias in the measurement, which was carried out with the rebreathing method on both occasions, but one possibility is that the first study was in the autumn of the year whereas the second was in the spring.
Discussion
Bacterial infection in chronic bronchitis is an intermittent complication, is variable and unpredictable, and consequently the results of chemoprophylaxis are difficult to assess. Our results show that, as one would expect, the most susceptible patients in terms of the frequency of exacerbations are those who benefit most from chemoprophylaxis. The level which appears to justify chemoprophylaxis is more than one exacerbation each winter. At levels below this we agree with Malone et al. (1968) that early treatment for clearly defined exacerbations with purulent sputum will achieve satisfactory results.
Our repeated observations on 24-hour sputum samples showed a progressive clearing of pus with increasing duration of chemoprophylaxis and a slight reduction in sputum volume, but the results wee not statistically sgnificnt and the assessment was complicated by continuing intermittent therapy.
Tetracycline toxicity has been negligible. The isolation of tetracycline-resistant coagulase-positive staphylococci among patients on tetracycline prophylaxis has been discussed by Wade et a{. (1967) , who found no evidence of frequent or dangerous proliferation of drug-resistant organisms in the sputum. None of our patients developed a progressive staphylococcal infection.
In the Medical Research Council (1966) trial the rate of decline in F.E.V.1 over a five-year period was unaffected by chemoprophylaxis, but the patients were suffering from early chronic bronchitis and the average F.E.V.1 was just over 2 litres. Their annual decline in F.E.V.1 was 4%, which is similar to that reported by Jones et at. (1967) in a more disabled group of patients who were not receiving chemoprophylaxis. In our study the disability of the patients was intermediate and the average annual decline in absolute F.E.V., was 55% in the placebo group compared with 2-6%, 3-8%, and 3-6% in the other treatment groups. This suggests an advantage for those receiving chemoprophylaxis for two, three, or five years, but the results do not achieve statistical significance. We suspect from our other evidence that probably there is slower deterioration in lung function when chemoprophylaxis is given, but we believe that more frequent serial measurements over a long period of study will be necessary to establish this in patients with moderate disability.
